SAN DIEGO and CALGARY, AB - Oncolytics Biotech Inc. (NASDAQ: NASDAQ:ONCY) (TSX: ONC), a biotechnology firm focused on immunotherapy for cancer, has received a notification from the Nasdaq regarding ...

Oncolytics (ONCY) announced that it received a delinquency notification letter from Nasdaq indicating that the company is not currently in ...

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...

After its depression candidate failed a phase 3 trial and disappointed analysts, Neumora is shaking up its leadership team.

Replimune's innovative cancer therapies, strong cash reserves, and FDA support position it to disrupt oncology markets. Click ...

that partners with biotech and small to mid-size pharma companies to accelerate the development of advanced and novel therapeutics, has released its latest report, Oncolytic Virus Therapy ...

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...

Venture Symbol: SRR All Issues: Yes Resumption (ET): 9:30 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company.

Tax advantages offered by PEA-PME and PEA are only available to French residents. *Shares of European companies with fewer than 5,000 employees and an annual revenue of less than €1.5 billion or total ...

Oncolytics Biotech (NASDAQ:ONCY – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $5.00 target price on ...

The market is estimated to grow at a CAGR of 8.73% during the forecast period.... 7 fév 2025 Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of ...

H.C. Wainwright reaffirmed a Buy rating on Oncolytics Biotech (NASDAQ:ONCY) shares with a steady price target of $5.00. The stock, currently trading at $0.73 and near its 52-week low, shows potential ...